Print

EndoGastric Solutions, Inc. Completes Patient Enrollment in Clinical Trial Comparing TIF Procedure to PPI Therapy for the Treatment of GERD  
10/2/2012 10:11:13 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal treatment of Gastroesophageal Reflux Disease (GERD), today announced the completion of enrollment in its Transoral Incisionless Fundoplication (TIF®) versus Medical Proton Pump Inhibitor (PPI) Management of Refractory GERD Symptoms (TEMPO) clinical trial, which will generate U.S. Level I evidence for TIF. The trial is designed to assess the safety and efficacy of the TIF procedure as compared to PPI therapy to treat bothersome symptoms associated with chronic GERD.
//-->